Thursday - June 25, 2026

Category Archives: Science

Glioma Pipeline Insights Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Glioma Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma therapeutics … Continue reading →

Chronic and Acute Pain Pipeline Insights Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Chronic and Acute Pain Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Chronic and Acute Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Alzheimer’s Disease Pipeline Insights Accelerates as 200+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Alzheimer’s disease Pipeline Insight, 2026” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Alzheimer’s disease pipeline landscape. It covers the Alzheimer’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

AAV Vectors in Gene Therapy in Gene Therapy Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies and 250+ pipeline drugs in AAV Vectors in Gene Therapy pipeline landscape. It covers the AAV Vectors in Gene Therapy pipeline drug … Continue reading →

Generalized Myasthenia Gravis Pipeline Accelerates as 10+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Generalized Myasthenia Gravis Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Generalized Myasthenia Gravis (gMG) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Fibromyalgia Pipeline Accelerates as 8+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Fibromyalgia Pipeline Insight 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Fibromyalgia pipeline landscape. It covers the Fibromyalgia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Fibromyalgia pipeline therapeutics … Continue reading →

Transcatheter Aortic Valve Replacement Market to Reach USD 7.64 Billion by 2032, Driven by Rising Aortic Stenosis Burden and Expanding TAVR Adoption

Global Transcatheter Aortic Valve Replacement (TAVR) Market is witnessing remarkable growth as increasing prevalence of aortic stenosis, expanding indications for minimally invasive cardiac procedures, and continuous technological innovations accelerate demand for next-generation transcatheter heart valves worldwide. DelveInsight’s latest market analysis … Continue reading →

KRAS Inhibitors Market is Poised for Robust Growth by 2036 Driven by Expanding KRAS-Targeted Therapies and Rising Adoption Across Multiple Oncology Indications | DelveInsight

The KRAS Inhibitors Market is witnessing significant momentum driven by increasing adoption of precision oncology, growing biomarker testing rates, expanding treatment opportunities across KRAS-mutated cancers, and the emergence of next-generation KRAS-targeted therapies. The anticipated launch of novel therapies such as … Continue reading →

Parkinson’s Disease Psychosis Market is Expected to Witness Steady Growth by 2036, Driven by Rising Disease Burden and Emerging Novel Therapies | DelveInsight

Parkinson’s Disease Psychosis Market is experiencing steady growth, driven by the rising prevalence of Parkinson’s disease, increasing recognition of non-motor symptoms, improved diagnosis rates of PDP, and growing adoption of targeted treatment options. Furthermore, the development of emerging therapies, including … Continue reading →

Diabetic Neuropathy Market is Expected to Witness Significant Growth by 2036 Driven by Rising Diabetes Prevalence and Emerging Disease-Modifying Therapies | DelveInsight

The Diabetic Neuropathy Market is witnessing substantial growth driven by the increasing prevalence of diabetes mellitus, rising burden of diabetic complications, growing awareness of neuropathic disorders, and increasing demand for effective pain management therapies. Additionally, the anticipated launch of emerging … Continue reading →